OR WAIT 15 SECS
Volume 39, Issue 8
The cell and gene therapy space remains fertile territory for growth, exploration, and discovery. How applying a data-driven model may be the best way to approach this complex ecosystem and assess the innovations of tomorrow.
Despite the emergence of approved treatments in the field, the cell and gene therapy space remains fertile territory for growth, exploration, and discovery. How applying a data-driven model may be the best way to approach this diverse ecosystem and assess the innovations of tomorrow
Each passing year, the success of cell and gene therapy becomes clearer, more widely covered in the media, and is increasingly the focus of a rapidly growing society of researchers. Making sense of this extensive ecosystem is no small feat, but by using a data-driven approach, the life sciences industry can get closer to determining what the future holds for cell and gene therapy.
The idea of inserting a gene into a patient’s cells to treat or prevent disease has emerged as one of the most exciting areas of biotechnology. Its buzz can be attributed to the hope these therapies hold for patients with rare and often deadly inherited diseases; the scientific promise and intrigue of gene editing; and the business opportunity that these revolutionary therapies with lucrative price tags hold.
But what do we really know about cell and gene therapy? What proverbial gold will be found at the end of this rainbow?
The plethora of medical conditions that cell and gene therapies are being evaluated for is ever expanding, however, oncological disorders remain the most commonly explored. Last year’s Nobel Prize in Medicine awarded to a pair of cancer immunotherapy researchers marked an important milestone in the development of such therapeutics. The works of Dr. James P. Allison and Dr. Tasuku Honjo uncovered the role of checkpoint inhibitors in the body’s immune response to cancer. Checkpoint inhibitors work by re-engaging the checkpoints on T-cells, which are the cells within the immune system that fight cancer. When cancer cells shut down these checkpoints on T-cells, they are unable to fight off the cancer cells.
Through their work, Allison and Honjo deciphered exactly how cells were interacting so they could fine-tune methods to recruit and control the immune system in fighting cancer. Their findings scientifically bolstered the foundation of a new principle for cancer treatments: immunotherapy.
The researchers’ discoveries ultimately led to a new class of drugs that has already resulted in lasting remission in several patients. The first drugs to make it to market based on the Nobel Prize winning research include Yervoy, Opdivo, and Keytruda. Allison discovered the checkpoint inhibitor CTLA-4 (the target of Yervoy) and Honjo discovered the checkpoint inhibitor PD-1 (the target of Opdivo and Keytruda).
These breakthroughs helped expand the field of T-cell therapy, which by 2017, notably delivered the first approvals of CAR T-cell medicines Kymriah and Yescarta, which treat blood cancers.
Cell and gene therapy provides an almost unlimited source of innovation. These therapies offer personalization and show potential relevance across multiple conditions, as evidenced by recent product approvals for spinal muscular atrophy (Zolgensma), inherited retinal dystrophy (Luxturna), and beta thalassemia (Zynteglo), a rare genetic blood disorder. Across most of the diseases being tested, competition is low despite an increasing amount of therapeutic potential and advanced maturity.
Making sense of this extensive ecosystem can be a difficult task; however, by using a data-driven approach of exploring the cell and gene therapy space, one can potentially map out the opportunity areas to determine where the future of cell and gene therapy is heading.
At Signals Analytics, for example, to prioritize opportunities, we’ve broken the ecosystem down using three key parameters:
We’ve also mapped out four cohorts in which innovation is taking place:
Presented ahead are learnings from this breakdown, and what will likely be some of the most innovative efforts that will reach the market in the next three to 10 years.
In response to the opioid public health crisis, there has been a natural shift toward newer, natural, and non-addictive alternatives for treating pain. Simultaneously, there is growing research into cell and gene therapy treatment options for patients with neuropathic pain who respond poorly to opioid and over-the-counter analgesics.
Of these recent innovations is a cell therapy targeted specifically for treating the pain experienced in musculoskeletal conditions, mostly osteoarthritis, by using mesenchymal stem cells (MSCs) from adipose tissue. These cells promote the body’s natural healing by reducing inflammation, promoting tissue repair, and reducing scarring, and can relieve neuropathic pain when injected directly into an affected joint or tendon.
Australian regenerative medicine company Regeneus is developing a portfolio of innovative cell-based therapies with an initial focus on osteoarthritis. Progenza, its allogeneic off-the-shelf adipose-derived MSCs, are currently being evaluated for reducing knee pain and improving cartilage volume in osteoarthritic patients.
Progenza differentiates itself from other MSC therapies since it includes cell secretions, which improve the functionality of the MSCs post-thawing. In addition, the company claims that the use of MSCs from adipose tissue assists in scaling the manufacturing of these cells.
While more research is needed to establish that such an approach would also be applicable for solving the opioid crisis, early positive signals are emerging for the use of stem cells for opioid therapy, according to a 2018 study by the Cleveland Clinic. In its study, MSCs transplantation showed long-lasting and consistent opioid tolerance (OT) and opioid-induced hyperalgesia (OIH) in rat and mouse models. These results indicate that stem cell therapy may be able to prevent and reverse OT and OIH, which are key issues faced by patients prescribed to opioid therapy.
Innovations grouped in this cohort are projected to hit the market, if successful, within three to five years. Unsurprisingly, the majority of cell and gene therapies that are being explored here are for treating various types of cancers.
Hematological malignancies such as acute myelogenous leukemia, chronic lymphocytic leukemia, and myelodysplastic syndrome are more advanced and have attracted more attention from a competition perspective. Solid cancers are catching up with significant efforts being invested into developing cell and gene therapies for treating such conditions.
Huntington’s disease, a relatively rare genetic condition, remains incurable, and this is despite the medical advances that have taken place in the neurological space. The disease is typically inherited and caused by an autosomal dominant mutation in either of an individual’s two copies of a gene called Huntingtin (HTT). When mutated, the result is an abnormal protein which gradually damages cells in the brain.
Some of the key research efforts around this disease are targeted at establishing safe and efficient methods for lowering total or mutant HTT expression in the brain. One research group from Jinan University has been evaluating how CRISPR/Cas9-mediated inactivation can effectively deplete mutant protein aggregates and attenuate early neuropathology.
Simultaneously, uniQure has been testing ways to suppress mutant protein expression by using engineered microRNAs targeting HTT transcripts that are delivered by the adeno-associated viral vector AAV5.
Research into Huntington’s disease is still developing; however, its advancement is sure to be supported by the growing body of research and grants focusing on cell and gene therapies for treating this rare disease.
This opportunity cohort is about five to six years away from potentially reaching the market and comprises innovations at preclinical or very early Phase 1 clinical trials. The top medical conditions being evaluated include oncological disorders such as endometrial cancer, chronic myeloid leukemia (CML), and soft tissue carcinoma, and immunological and infectious diseases such as Sjogren’s syndrome, tuberculosis, hepatitis B virus, and urinary tract infections, among others.
Of particular interest is the application of cell and gene therapies for treating cystic fibrosis (CF) patients who experience persistent lung infections, which limit their ability to breathe over time. In these patients, a defective gene causes a thick and sticky buildup of mucus in the lungs, pancreas, and other organs.
Gene therapy is an ideal treatment method for CF, and this major shift in medicine allows for the correction of the underlying genetic cause of a disease such as CF as opposed to merely treating its symptoms. The process typically involves packaging healthy genes into altered viruses, which then act as a vector to deliver a dose either into the bloodstream or the disease affected area. However, in the lungs of these patients, bacteria collect in the airways and biofilms form, which present an additional barrier to penetrate the afflicted area with immune cells, antibiotics, or gene transfer technologies.
One of the most innovative and attractive areas we expect to see reaching the market for CF patients are various uses of nanomaterials for disease therapies. A team at French public research organization Inserm is evaluating aerosol delivery of nanocomplexes with encapsulated antibiotics and nucleic acids to eradicate the bacteria causing infections and allow for effective transfer of the gene therapy itself.
At the University of The Basque Country, researchers are exploring pulmonary delivery of tobramycin-loaded nanostructured lipid carriers for CF related pseudomonas aeruginosainfections. Their work is focused on characterizing lipid nanoparticles for pulmonary delivery of tobramycin. Both these findings could be an encouraging alternative to the currently available CF therapy options.
This group of opportunities is the furthest away from hitting the market. There are still likely eight to 10 years before these innovations come to fruition; however, it’s also a fertile ground to test new concepts. The key medical conditions being evaluated in this cohort are ulcerative colitis (UC) as well as a variety of pulmonary disorders such as respiratory failure, pulmonary edema, and pulmonitis.
Innovative therapies for UC, a condition that results in inflammation and ulcers of the colon and rectum, are focused primarily on two types of cell therapies that reduce inflammation: hematopoietic stem cell therapies and conditioned immune cell therapy, including mesenchymal stem cells and T-regulatory cells-based therapies.
An innovative take on these types of therapies comes from a research group at the Friedrich-Alexander Universität Erlangen-Nürnberg in Germany. It is believed that a local imbalance between regulatory (Treg) and effector T-cells plays a major role in gut-specific inflammation. Restoration of this balance through an adoptive Treg transfer is an attractive new treatment approach in patients who are refractory to current standard therapies. This research group has established autologous GMP-ready regulatory T-cells for Treg-based cell therapy.
Additional innovative efforts for treating UC can be seen in the use of nanoparticles to deliver anti-inflammatory relief to the bowel. A research group at Georgia State University is focusing on using nanoparticles that are capable of colitis tissue-targeted delivery and site-specific drug release that will overcome
the challenges of oral drug delivery. Some of these challenges include the instability of drugs in the gastrointestinal tract, low targeting of disease tissues, and severe adverse effects. Nanoparticles may offer a unique and therapeutically effective system that addresses these issues.
As is true for many new ecosystems, the cell and gene therapy space is booming with extensive evaluations of multiple diseases, formats, and technologies-resulting in a few anticipated treatment approvals and launches in recent years. As this space matures and is bolstered with even more scientific evidence, we can anticipate a more narrowed focus of R&D efforts, which will enable the maturation of these therapies. Until then, we’ll bask in the rays of all this scientific ingenuity but continue to take a data-driven approach.
Lital Aravot is Commercial Growth Executive, Signals Analytics